Several analysts have recently updated their ratings and price targets for Medpace (NASDAQ: MEDP): 3/24/2020 – Medpace was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services […]